Enhanced Test Helps Clinicians Select Medications for PTSD, Depression and Anxiety

GeneSight® Psychotropic test now provides clinicians a way to treat depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other behavioral health disorders with pharmaceutical accuracy based on a patients individual genetic makeup, and how those genes may react with the chemical composition of a specific drug. This break-through allows clinicians to remove the trial and error system currently used for prescription pharmaceuticals, allowing them to select medication based on the patients specific genes that match certain drug types, whilst discarding others. Pharmacological treatment for depression varies from 40 to 60 percent success, with remission rates between 30 - 45 percent. That means that pharmacological intervention for depression has an extremely low longevity success rate. With more than 785,000 possible gene-drug combinations available to generate personalized patient reports, clinicians have a 36hr turnaround in receiving a com
https://www.ptsdnews.com/item/2-enhanced-test-helps-clinicians-select-medications-for-ptsd-depression-and-anxiety